ANTICOAGULANTS AND CORTICOSTEROIDS IN COVID-19 – WHAT DO WE KNOW SO FAR?

  • Marija Milenković Urgentni centar, Univerzitetski Klinički centar Srbije, Beograd, Srbija
  • Marija Dukić Kliničko-bolnički centar Bežanijska kosa, Beograd, Srbija
  • Ivan Rović Medicinski fakultet Univerziteta u Beogradu, Beograd, Srbija
  • Đuro Šijan Medicinski fakultet Univerziteta u Beogradu, Beograd, Srbija
  • Adi Hadžibegović Urgentni centar, Univerzitetski Klinički centar Srbije, Beograd, Srbija
  • Višeslav Popadić Kliničko-bolnički centar Bežanijska kosa, Beograd, Srbija
  • Slobodan Klašnja Kliničko-bolnički centar Bežanijska kosa, Beograd, Srbija
  • Milica Brajković Kliničko-bolnički centar Bežanijska kosa, Beograd, Srbija
  • Marija Zdravković Kliničko-bolnički centar Bežanijska kosa, Beograd, Srbija
DOI: https://doi.org/10.5937/3-35014
Keywords: COVID-19, SARS-CoV-2, anticoagulants, thrombosis, corticosteroids

Abstract


It has been a year and a half since the fight against the COVID-19 pandemic started. In today’s protocols for the treatment of COVID-19 and the prevention of its complications, corticosteroid therapy and anticoagulant therapy have a crucial part. The goal of this article is to show, based on available data, both the benefits and the disadvantages of corticosteroid and anticoagulant therapy in treating the infection caused by the Sars-CoV-2 virus. At the very onset of the pandemic, an increased frequency of thrombotic events negatively impacting the course and outcome of the disease, was registered. It has been observed that increased values of D-dimer in patients with COVID-19 do not correlate with the presence of venous thrombosis and are not reliable in the detection of deep vein thrombosis and pulmonary thromboembolism. According to the National Protocol for Treating COVID-19 (Version 12), anticoagulant therapy is recommended in hospitalized patients. Due to the risk of different side effects, such as bleeding and heparin-induced thrombocytopenia, a careful use of anticoagulant therapy is necessary, as well as close monitoring of its effects. With respect to corticosteroids, their efficacy in patients with moderate and severe clinical presentation of COVID-19, who are in need of oxygen support, was analyzed. Corticosteroids have proven efficient in decreasing mortality, decreasing the need for mechanical ventilation, decreasing the length of stay in intensive care units, as well as in shortening the length of hospital stay. Assessing the individual benefits and risks before introducing these drugs into the therapy of a patient with confirmed COVID-19 is of vital importance for achieving the desired effects of the therapy.

References


  1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372.

  2. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730-1741.

  3. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, Boscolo-Rizzo P. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA. 2020 May 26;323(20):2089-2090.

  4. World Health Organisation. Overview of Coronavirus (COVID-19). Dostupno na: https://covid19.who.int/ (Pristupljeno 14. novembra 2021)

  5. White-Dzuro G, Gibson LE, Zazzeron L, White-Dzuro C, Sullivan Z, Diiorio DA, Low SA, Chang MG, Bittner EA. Multisystem effects of COVID-19: a concise review for practitioners. Postgrad Med. 2021 Jan;133(1):20-27.

  6. DeWald TA, Washam JB, Becker RC. Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications. Neurosurg Clin N Am. 2018 Oct;29(4):503-515.

  7. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. Journal of Medical Virology. 2021;93(1):250–6.

  8. Zhang Y, Chen Y, Meng Z. Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. Front Immunol. 2020 Nov 9;11:577442.

  9. Rhen T, Cidlowski JA. Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs. N Engl J Med. 2005 Oct 20;353(16):1711–23.

  10. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology. 2017 Jan;76(1):11–6.

  11. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147.

  12. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020; 142(2): 184-186.

  13. Wu C, Liu Y, Cai X, Zhang W, Li Y, Fu C. Prevalence of Venous Thromboembolism in Critically Ill Patients With Coronavirus Disease 2019: A Meta-Analysis. Front Med (Lausanne). 2021 Apr 29;8:603558.

  14. Mansory EM, Srigunapalan S, Lazo-Langner A. Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis. TH Open. 2021 Jul 6;5(3):e286-e294.

  15. Aguilera-Alonso D, Murias S, Martínez-de-Azagra Garde A, Soriano-Arandes A, Pareja M, Otheo E, Moraleda C, Tagarro A, Calvo C; EPICO-AEP Working Group. Prevalence of thrombotic complications in children with SARS-CoV-2. Arch Dis Child. 2021 Nov;106(11):1129-1132.

  16. Mai V, Tan BK, Mainbourg S, Potus F, Cucherat M, Lega JC, Provencher S. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vascul Pharmacol. 2021 Aug;139:106882.

  17. Tufano A, Rendina D, Abate V, Casoria A, Marra A, Buonanno P, Galletti F, Di Minno G, Servillo G, Vargas M. Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. J Clin Med. 2021 Oct 25;10(21):4925.

  18. Ali MAM, Spinler SA. COVID-19 and thrombosis: From bench to bedside. Trends Cardiovasc Med. 2021 Apr;31(3):143-160.

  19. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418.

  20. Dimitropoulou C, Chatterjee A, McCloud L, Yetik-Anacak G, Catravas JD. Angiotensin, bradykinin and the endothelium. Handb Exp Pharmacol. 2006;(176 Pt 1):255-94. 

  21. Leebeek FW, Eikenboom JC. Von Willebrand's Disease. N Engl J Med. 2016 Nov 24;375(21):2067-2080. 

  22. Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020 Aug;7(8):e575-e582.

  23. Ali MAM, Spinler SA. COVID-19 and thrombosis: From bench to bedside. Trends Cardiovasc Med. 2021 Apr;31(3):143-160.

  24. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020 May 29;5(1):84.

  25. Pulivarthi S, Gurram MK. Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. N Am J Med Sci. 2014; 6(10): 491-9.).

  26. Thachil J, Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism? Semin Thromb Hemost. 2020 Oct;46(7):777-780.

  27. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020;48(9):1358-1364

  28. Pelemis M, Stevanovic G, Turkulov V, Matijasevic V, Milosević B, Milosevic I, et al. Nacionalni protocol za lečenje pacijenata sa COVID19 infekcijom (verzija 12). 2021 Sep.

  29. Du WN, Zhang Y, Yu Y, Zhang RM. D-dimer levels is associated with severe COVID-19 infections: A meta-analysis. Int J Clin Pract. 2021;75(8):e14031.).

  30. Popadic V, Klasnja S, Milic N et al. Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy. Oxid Med Cell Longev. 2021 Apr 20;2021:6648199. doi: 10.1155/2021/6648199. eCollection 2021.

  31. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.

  32. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2245-2249.

  33. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020; 18(6):1324-1329.

  34. ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802.

  35. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789.

  36. Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021;326(17):1703–1712)

  37. Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015 Jan;16(1):11-7. 

  38. Sartori MT, Prandoni P. How to effectively manage the event of bleeding complications when using anticoagulants. Expert Rev Hematol. 2016 Jan;9(1):37-50

  39. Lee GM, Arepally GM. Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2013;2013:668-74.

  40. Daviet F, Guervilly C, Baldesi O, Bernard-Guervilly F, Pilarczyk E, Genin A, Lefebvre L, Forel JM, Papazian L, Camoin-Jau L. Heparin-Induced Thrombocytopenia in Severe COVID-19. Circulation. 2020 Nov 10;142(19):1875-1877.

  41. Tran PN, Tran MH. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia. Clin Appl Thromb Hemost. 2018 Mar;24(2):201-209. 

  42. Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vasc Med. 2020 Apr;25(2):160-173.

  43. Chaudhuri, D., Sasaki, K., Karkar, A. et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med (2021))

  44. Añón JM, Villar J. Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Intensive Care Med. 2021 Mar;47(3):355-356.

  45. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al., on behalf of the RECOVERY Collaborative Group. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. MedRxiv. 2020

  46. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. 2020;324(13):1307–1316.                     

  47. Villar J, Añón JM, Ferrando C, Aguilar G, Muñoz T, Ferreres J, et al. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. Trials. 2020 Aug 16;21(1):717

  48. Corral-Gudino, L., Bahamonde, A., Arnaiz-Revillas, F. et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: An open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr 133, 303–311 (2021)

  49. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clinical Infectious Diseases. 2020 Aug 12;ciaa1177

  50. Ranjbar, K., Moghadami, M., Mirahmadizadeh, A. et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 21, 337 (2021)

  51. Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. J Intensive Care Med. 2021 Feb 25;0885066621994057

  52. Dequin P, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. 2020;324(13):1298–1306

  53. The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.  2020;324(13):1317–1329

  54. Milenkovic M, Dukic M, Brajkovic M, Klasnja S, Tosković B, Zdravkovic M. Primena Kortikosteroida U Terapiji COVID-19 Infekcije (Kortikosteroidi U COVID-19 Infekciji). SJAIT.2021;(43)VII – IX)

  55. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology. 2017 Jan;76(1):11–6

  56. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology. 2017 Jan;76(1):1–9.

Published
2022/03/24
Issue
Vol. 3 No. 1 (2022): Serbian Journal of the Medical Chamber
Section
Reviews